Last: | $1.595 |
---|---|
Change Percent: | -8.12% |
Open: | $1.73 |
Close: | $1.595 |
High: | $1.73 |
Low: | $1.54 |
Volume: | 10,251 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.595 | $1.73 | $1.595 | $1.73 | $1.54 | 10,251 | 07-26-2024 |
$1.6 | $1.52 | $1.6 | $1.73 | $1.51 | 7,520 | 07-25-2024 |
$1.64 | $1.55 | $1.64 | $1.71 | $1.51 | 49,077 | 07-24-2024 |
$1.56 | $1.5091 | $1.56 | $1.61 | $1.44 | 39,200 | 07-23-2024 |
$1.48 | $1.47 | $1.48 | $1.51 | $1.36 | 8,130 | 07-22-2024 |
$1.5 | $1.55 | $1.5 | $1.58 | $1.39 | 41,202 | 07-19-2024 |
$1.46 | $1.49 | $1.46 | $1.675 | $1.46 | 48,373 | 07-18-2024 |
$1.49 | $1.49 | $1.49 | $1.52 | $1.4201 | 37,491 | 07-17-2024 |
$1.54 | $1.55 | $1.54 | $1.6001 | $1.36 | 29,722 | 07-16-2024 |
$1.49 | $1.45 | $1.49 | $1.53 | $1.4104 | 13,527 | 07-15-2024 |
$1.455 | $1.42 | $1.455 | $1.55 | $1.39 | 22,205 | 07-12-2024 |
$1.36 | $1.28 | $1.36 | $1.5299 | $1.23 | 25,659 | 07-11-2024 |
$1.31 | $1.31 | $1.31 | $1.37 | $1.26 | 34,212 | 07-10-2024 |
$1.336 | $1.42 | $1.336 | $1.42 | $1.25 | 16,390 | 07-09-2024 |
$1.35 | $1.2 | $1.35 | $1.39 | $1.2 | 41,126 | 07-08-2024 |
$1.16 | $1.2 | $1.16 | $1.4 | $1.14 | 40,441 | 07-05-2024 |
$1.1505 | $1.15 | $1.1505 | $1.255 | $1.145 | 68,062 | 07-04-2024 |
$1.1505 | $1.15 | $1.1505 | $1.255 | $1.145 | 68,062 | 07-03-2024 |
$1.21 | $1.3099 | $1.21 | $1.3099 | $1.2 | 14,775 | 07-02-2024 |
$1.24 | $1.24 | $1.24 | $1.27 | $1.13 | 44,339 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Inhibikase Therapeutics Inc. Company Name:
IKT Stock Symbol:
NASDAQ Market:
Inhibikase Therapeutics Inc. Website:
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kin...
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson...